Across TCGA pan-cancer cohorts, KRTAP6-3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KRTAP6-3 data layer compared with 10 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher KRTAP6-3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP6-3 expression acts as an unfavorable survival marker.

PAAD, COAD, and UCEC are the cancer types where KRTAP6-3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.112	0.613	<.001	24	view →
COAD	OS	Median	All	0.168	0.806	.002	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: KRTAP6-3 tumor-vs-normal RNA expression · all KRTAP6-3 data types